Crinetics Pharmaceuticals, Inc.
CRNX
$28.53
-$0.71-2.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -328.25M | -298.41M | -277.91M | -258.54M | -235.46M |
| Total Depreciation and Amortization | 3.24M | 2.79M | 2.26M | 1.76M | 1.29M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 64.04M | 58.02M | 55.60M | 51.20M | 44.31M |
| Change in Net Operating Assets | -594.00K | 11.64M | 20.24M | 27.25M | 11.42M |
| Cash from Operations | -261.57M | -225.97M | -199.81M | -178.33M | -178.45M |
| Capital Expenditure | -3.75M | -3.84M | -3.75M | -6.72M | -6.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -657.34M | -570.97M | -116.29M | -327.21M | -242.86M |
| Cash from Investing | -661.09M | -574.82M | -120.04M | -333.94M | -248.86M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 654.93M | 1.06B | 514.05M | 814.54M | 822.07M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -33.63M | -50.93M | -19.73M | -39.67M | -40.04M |
| Cash from Financing | 621.30M | 1.01B | 494.32M | 774.87M | 782.03M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -301.36M | 209.65M | 174.47M | 262.61M | 354.73M |